The study shows that, during 2008, the rate of patients who suspended statin treatment was 22% lower than those on a brand name medication. The analysis also revealed that reaching the coverage gap stimulates the use of generics among all Medicare recipients. During the initial phase of the benefit, when the plan provides drug coverage, one third of the medications used daily by beneficiaries were generics, and two thirds were brand name drugs. Once beneficiaries reached the coverage gap, however, generic use rises to 72%, and brand name use falls to 28%.
0 Comments:
Post a Comment